Assessment of drug sensitivity of human leukaemic myeloblasts. I. Labelling human myeloblasts with 125IUdR for survival studies in mice.
The compound (125)IUdR can be incorporated in a stable form into the DNA of cells. The isotope is released if labelled cells or their progeny die. Consequently the rate of (125)I excretion from mice can be used to follow the fate of labelled cells in vivo. Using these principles we show:(1) Sufficient label can be incorporated in vitro into both fresh and cryopreserved human leukaemic myeloblasts, in non-toxic concentrations, to allow their survival in mice to be estimated by whole-body counting;(2) The release of isotope from labelled cells is sufficiently slow to offer reasonable expectation that this technique can be used for assessing the sensitivity of myeloblasts to cytotoxic agents in vivo (an application described in the second paper in this series, Sonis, Falcão and MacLennon, 1977);(3) The rate of (125)Iexcretion from mice injected with myeloblasts from different donors varies. This probably reflects different rates of spontaneous death of injected myeloblasts;(4) Active rejection of myeloblasts starts within 48 h of their injection into mice;(5) Indirect evidence that phagocytic cells may be active agents in myeloblast destruction in mice;(6) Various methods of immunologically depriving mice were assessed to see if they would result in a useful increase in survival of injected human myeloblasts. We conclude that there is little advantage and some limitations in using mice thus deprived;(7) One of the agents used for immunological deprivation-silica powder-markedly decreased the rate of (125)I loss from mice injected with labelled killed myeloblasts. This experience emphasizes the importance of including the killed-cell control in this assay.
D000818:Animals; D001773:Blood Cells / Q000378:metabolism; D001854:Bone Marrow Cells; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005615:Freezing; D007065:Idoxuridine / Q000378:metabolism; D066298:In Vitro Techniques; D007553:Isotope Labeling / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice
D007065:Idoxuridine
Br J Cancer. 1960 Mar;14:93-8
14422533
Fed Proc. 1964 May-Jun;23:640-8
14191970
Nature. 1965 May 29;206(987):949-50
5839861
Transplantation. 1966 Jul;4(4):438-51
5967867
Science. 1967 Sep 8;157(3793):1180-2
6038687
Radiat Res. 1970 Sep;43(3):663-78
5460398
Transplantation. 1975 Jan;19(1):77-81
1118889
Br J Cancer. 1977 Sep;36(3):307-12
270373
Br J Cancer. 1973 Mar;27(3):203-11
4511988
Br J Cancer. 1975 Oct;32(4):456-64
1082343
Cancer Res. 1976 May;36(5):1674-9
1063598